Our data suggest that the axis between myeloma cell lines (i.e., H929 and OPM2) and MSCs leads to a suppression of the SHH signaling pathway in MSCs, thus, probably reducing the endogenous potential to compensate for osteolytic complications of MM. This evidence concerns the gene SHH and Miyoshi myopathy.